Governance

Board and management

Meet our Board of Directors here

Meet our Management Team here

Shareholdings as of 7 July 2022 after rights issue and warrant exercise

The following entities hold more than 5% of the share capital and the voting rights in ViroGates:

  • N. P. Louis-Hansen ApS (Niels Peter Louis-Hansen) holds 25.64% of the shares and 26.76% of the voting rights
  • Ginnerup Capital ApS (Kim Ginnerup) holds 10.23% of the shares and 10.68% of the voting rights
  • 4AM ApS (Lars Krogsgaard, Board member) holds 10.23% of the shares and 10.67% of the voting rights

Governance documents

Articles of association

Appendix to Articles of association

Remuneration policy and guidelines for incentive pay

+800

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

suPAR is used in clinical routine in 38 hospitals

38 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling. This period covers October 1, 2021, until September 30, 2022.
Some hospital locations cannot be disclosed due to confidentiality.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates